^
    Back
    Association details:
    Biomarker:CCDC6-RET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug Class:RET inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    FP14.13 - Molecular Characterisation and Clinical Outcomes in RET Rearranged Non-Small Cell Lung Cancer (NSCLC)

    Published date:
    01/12/2021
    Excerpt:
    OS was also prolonged in CCDC6-RET fusion versus KIF5B-RET fusion positive patients (median 113.5 vs 37.7 months; HR 0.12, 95%CI 0.04-0.38, p=0.009)….In RET rearranged NSCLC, selective RET TKI therapy is associated with improved survival outcomes, especially in CCDC6-RET positive patients.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Eur J Med Chem
    Title:

    Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation

    Published date:
    08/06/2020
    Excerpt:
    We identified a lead compound, 59, which shows low nanomolar potency against RET-wt and RET V804M. Further 59 shows growth inhibition of LC-2/ad cells which RET-CCDC6 driven. We also determined that 59 is a type 2 inhibitor of RET and demonstrated its ability to inhibit migration of tumor cells...
    DOI:
    10.1016/j.ejmech.2020.112691